ARGENICA THERAPEUTICS LIMITED

ASX:AGNPharmaceuticals, Biotechnology & Life Sciences

128.5M shares on issueASX (delayed) · snapshot 11 Sept 2026129.0M fully diluted+0.4% if every option and right converts$0.16price · delayed$20.6Mmarket cap · indicative

Today’s holders own 99.6% of what they think they own, once every option and right converts.

Low

Dilution risk

Runway 2–4 quarters

Absolute levels — not a ranking against other companies.

Cash runway3.1 quarters of funding

Share-count growth (24m)1.0%

Raise cadence (24m)0 cash raises

Options & rights overhang0.4% of shares

In-the-money supply0.0% of shares

Pending proposed issuesnone

ARGENICA THERAPEUTICS LIMITED's ordinary share count was 128M as of July 2025, an increase of 1.0% from August 2024. The company has not raised capital in the past 24 months, and no proposed securities issues are pending. Options on issue could convert into 500,000 new shares, representing 0.4% of the current share count, with the nearest expiry in May 2027; none are currently in the money. As of the June 2026 quarter, the company reported A$5.1M in available cash, with a stated runway of 3.1 quarters.

AI-generated summary of this page's cited filings · updated 11 Sept 2026

Get told when this changes

Set up alerts

Daily email alerts cover risk-level moves, new raises, pending proposed issues and option expiries for the companies you follow.

0.4%

Options & rights overhang

0.0%

In-the-money supply

Raises · last 12 months

3.1 qtrs

Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue

Weekly counts from ASX records. Dots mark cash capital raises. Latest count 128.5M per ASX (delayed) (snapshot 11 Sept 2026).

Cash runway

3.1 qtrs

Two to four quarters of funding at the recent spend rate.

Funds operations to about Mar 2027 at the reported spend rate.

$5.0M cash after burn from the quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds. Filed with the quarterly report: $6.4M cash at quarter end (item 4.6), 4.0 qtrs of funding on the company’s own estimate. Our figure above carries the filed quarter-end balance forward at the reported spend rate and adds announced raise proceeds.

Free account

14 quarters on record — Cash runway history

Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.

Free account: 2 full company unlocks every month, no card.

Create free account See plans

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

Date	Form	Security	On issue, per this filing	Source
13 Aug 2026	3H · cancellation	AGN : ORDINARY FULLY PAID	128.5M	Appendix 3H
9 June 2026	3H · cancellation	AGN : ORDINARY FULLY PAID	128.5M	Appendix 3H
20 Oct 2025	3G · unquoted	AGN : ORDINARY FULLY PAID	128.5M	Appendix 3G
9 July 2025	2A · quoted issue	AGN : ORDINARY FULLY PAID	128.1M	Appendix 2A
9 July 2025	3H · cancellation	AGN : ORDINARY FULLY PAID	128.1M	Appendix 3H

Free account

22 filings on record — Full issuance history

Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).

Free account: 2 full company unlocks every month, no card.

Create free account See plans

Capital raises

No equity raises in the last 24 months.

Free account

Full raise history

Issue price, shares issued, brokers and stated purpose for every raise on record.

Free account: 2 full company unlocks every month, no card.

Create free account See plans

Forward supply

Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.

Free account

1 dated event on record — Forward supply calendar

Option expiries and proposed issues on one forward timeline, with the securities each could add.

Free account: 2 full company unlocks every month, no card.

Create free account See plans

Placement capacity

How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.

No Appendix 3B in the last 12 months reports an issue under the 15% placement capacity (as at 2026-09-12).

Free account

Placement capacity — LR 7.1 / 7.1A

The filings behind the figure: every Appendix 3B in the window with what it says was issued under 7.1 and 7.1A, each row linked to its filing, and how many shares are left.

Free account: 2 full company unlocks every month, no card.

Create free account See plans

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

0.4%

Options & rights overhang · of current shares

0.0%

In-the-money supply · at current price

500k

Potential new shares

May 2027

Nearest expiry

What a price move would switch on

At $0.16 today, 0 securities are in the money (0.0% of shares on issue). No more priced supply until 10× today’s price, which takes it to 500k (0.4% of shares).

Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.

Code	Security	Type	Exercise price	Expiry	On issue	Source
AGNAL	Options	Price-triggered	$0.93	31 May 2027	500k	Filing

“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.

1 class ceased in the last 12 months and is not counted above

The company’s own Appendix 2A restates each of these at zero. They are excluded from the overhang, the in-the-money supply and every figure on this page. Each count is the filing’s own count of securities in the class, not a share count — a 2A never states what one security converts into.